ClinicalTrials.gg
RecruitingNCT06952699Updated Oct 8, 2026

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

A Phase 2 interventional study of TAK-360 and Placebo in Narcolepsy Type 2, sponsored by Takeda. Recruiting at 52 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Planned enrollment
8th of 12
88 · median 95
Started
2025
with 1 other
Phase 2
6 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 12th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake.

The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that.

Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

03

Conditions studied

  • Narcolepsy Type 2

Browse trials for

Keywords

  • Narcolepsy without Cataplexy
  • NT2
  • TAK-360
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. The participant weighs greater than equal or to (≥)40 kilograms (kg) and has a (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) [inclusive].
  2. The participant has a documented, current diagnosis of NT2.

Key Exclusion Criteria:

  1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) other than NT2.
  2. The participant has medically significant thyroid disease.
  3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ [such as basal cell carcinoma] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor).
  4. The participant has any of the following viral infections based on a positive test result: surface antigen (at screening), virus (HCV) antibody (at screening), (HIV) antibody/antigen (at screening).
  5. The participant has a history of head injury or head trauma.
  6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
  7. The participant has a history of cerebral ischemia, (\<5 years from screening), intracranial aneurysm, or arteriovenous malformation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    TAK-360

    Participants will receive TAK-360 tablets, orally, for 4 weeks.

    Drug: TAK-360

  • Placebo comparator
    Placebo

    Participants will receive TAK-360 matching-placebo tablets, orally, for 4 weeks.

    Other: Placebo

Interventions

  • TAK-360 tablet.

  • OtherPlacebo

    TAK-360 matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

    Time frame: Up to 15 Weeks

Secondary outcomes

  1. Change from Baseline at Week 4 in Epworth Sleepiness Scale (ESS) Total Score

    The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.

    Time frame: Baseline, Week 4

  2. Change from Baseline at Week 4 in Mean Sleep Latency on the Maintenance of Wakefulness Test (MWT)

    The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions done 2 hours apart. Sleep latency in each session will be recorded. Participants will be required to stay awake in between the 4 sessions.

    Time frame: Baseline, Week 4

07

Study locations

44 of 52 sites recruiting
  • Takeda Site 36
    Auburn, Alabama 36832, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Takeda Site 39
    Chandler, Arizona 85224, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Takeda Site 40
    Chula Vista, California 91910, United States
    Recruiting
  • Takeda Site 14
    Redwood City, California 94063-3132, United States
    Recruiting
  • Takeda Site 10
    Santa Ana, California 92705-8519, United States
    Recruiting
  • Takeda Site 1
    Colorado Springs, Colorado 80918-3408, United States
    Recruiting
  • Takeda Site 48
    Bradenton, Florida 34209, United States
    Recruiting
  • Takeda Site 13
    Brandon, Florida 33511-5719, United States
    Recruiting
  • Takeda Site 46
    Jacksonville, Florida 32209, United States
    Recruiting
  • Takeda Site 44
    Miami, Florida 33155, United States
    Recruiting
  • Takeda Site 35
    Miami, Florida 33176, United States
    Recruiting
  • Takeda Site 3
    Orlando, Florida 32803-1468, United States
    Recruiting
  • Takeda Site 33
    Orlando, Florida 32807, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Takeda Site 32
    Atlanta, Georgia 30328, United States
    Recruiting
  • Takeda Site 49
    Bowie, Maryland 20715, United States
    Recruiting
  • Takeda Site 50
    Lansing, Michigan 48911, United States
    Recruiting
  • Takeda Site 34
    Lathrup Village, Michigan 48076, United States
    Recruiting
  • Takeda Site 4
    St Louis, Missouri 63123-6968, United States
    Recruiting
  • Takeda Site 37
    Middletown, New Jersey 07748, United States
    Recruiting
  • Takeda Site 8
    Denver, North Carolina 28037, United States
    Recruiting
  • Takeda Site 6
    Huntersville, North Carolina 28078-5082, United States
    Recruiting
  • Takeda Site 41
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Takeda Site 5
    Cincinnati, Ohio 45245-4500, United States
    Recruiting
  • Takeda Site 45
    Cleveland, Ohio 44106, United States
    Recruiting
  • Takeda Site 2
    Columbia, South Carolina 29201-2923, United States
    Recruiting
  • Takeda Site 38
    Austin, Texas 78731, United States
    Recruiting
  • Takeda Site 43
    Dallas, Texas 75235, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Takeda Site 42
    El Paso, Texas 79912, United States
    Completed

    Not enrolling at this site — choose another above.

  • Takeda Site 47
    Mansfield, Texas 76063, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Takeda Site 7
    San Antonio, Texas 78229-4849, United States
    Recruiting
  • Takeda Site 11
    Norfolk, Virginia 23510-1021, United States
    Recruiting
  • Takeda Site 28
    Beijing, Beijing Municipality 100053, China
    Recruiting
  • Takeda Site 29
    Guangzhou, Guangzhou 510515, China
    Recruiting
  • Takeda Site 51
    Changchun, Jilin 130021, China
    Recruiting
  • Takeda Site 27
    Shanghai, Shanghai Municipality 200040, China
    Recruiting
  • Takeda Site 17
    Montpellier, Hérault 34090, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Takeda Site 15
    Paris, 75013, France
    Recruiting
  • Takeda Site 22
    Rome, Lazio 133, Italy
    Recruiting
  • Takeda Site 31
    Verona, Veneto 37134, Italy
    Recruiting
  • Takeda Site 23
    Bologna, 40139, Italy
    Recruiting
  • Takeda Site 24
    Kohoku-ku, Yokohama-Shi, Kanagawa 222-0033, Japan
    Recruiting
  • Takeda Site 9
    Kumamoto, Kumamoto 862-0954, Japan
    Recruiting
  • Takeda Site 53
    Isahaya-shi, Nagasaki 854-0081, Japan
    Recruiting
  • Takeda Site 30
    Urasoe-Shi, Okinawa 901-2132, Japan
    Recruiting
  • Takeda Site 20
    Shinjuku-ku, Tokyo 162-0851, Japan
    Recruiting
  • Takeda Site 26
    Sumida-Ku, Tokyo 130-0004, Japan
    Recruiting
  • Takeda Site 52
    Fukuoka, 812-0025, Japan
    Recruiting
  • Takeda Site 12
    Yodogawa-ku, Osaka-shi, Ôsaka 532-0003, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Takeda Site 16
    Junggu, Daegu Gwang'yeogsi, South Korea
    Recruiting
  • Takeda Site 19
    Suwon, Gyeonggido 16247, South Korea
    Recruiting
  • Takeda Site 21
    Seoul, Seoul Teugbyeolsi 3080, South Korea
    Recruiting
  • Takeda Site 18
    Madrid, 28046, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 1, 2025
StartActual
May 6, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (3 now active, not recruiting, 1 now completed)
Show 4 sites
  • Takeda Site 36 · Auburn, United StatesRecruiting→Active, not recruiting
  • Takeda Site 33 · Orlando, United StatesRecruiting→Active, not recruiting
  • Takeda Site 42 · El Paso, United StatesRecruiting→Completed
  • Takeda Site 12 · Yodogawa-ku, Osaka-shi, JapanRecruiting→Active, not recruiting
across 2 updates, Oct 7, 2026 – Oct 8, 2026
Show all 2 updates
  1. Oct 8, 2026
    2 sites changed recruiting status (1 now recruiting, 1 now completed)
    Show 2 sites
    • Takeda Site 10 · Santa Ana, United StatesActive, not recruiting→Recruiting
    • Takeda Site 42 · El Paso, United StatesActive, not recruiting→Completed
  2. Oct 7, 2026
    5 sites changed recruiting status (5 now active, not recruiting)
    Show 5 sites
    • Takeda Site 36 · Auburn, United StatesRecruiting→Active, not recruiting
    • Takeda Site 10 · Santa Ana, United StatesRecruiting→Active, not recruiting
    • Takeda Site 33 · Orlando, United StatesRecruiting→Active, not recruiting
    • Takeda Site 42 · El Paso, United StatesRecruiting→Active, not recruiting
    • Takeda Site 12 · Yodogawa-ku, Osaka-shi, JapanRecruiting→Active, not recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06952699
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 1, 2025
Start date
May 6, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-360

Start the discussion